Kiessling Michael K, Klemke Claus D, Kaminski Marcin M, Galani Ioanna E, Krammer Peter H, Gülow Karsten
Tumor Immunology Program, German Cancer Research Center (DFKZ), Heidelberg, Germany.
Cancer Res. 2009 Mar 15;69(6):2365-74. doi: 10.1158/0008-5472.CAN-08-3221. Epub 2009 Mar 3.
Aberrant signaling of the nuclear facotr (NF-kappaB) pathway has been identified as a mediator of survival and apoptosis resistance in leukemias and lymphomas. Here, we report that cell death of cutaneous T-cell lymphoma cell lines induced by inhibition of the NF-kappaB pathway is independent of caspases or classic death receptors. We found that free intracellular iron and reactive oxygen species (ROS) are the main mediators of this cell death. Antioxidants such as N-Acetyl-l-cysteine and glutathione or the iron chelator desferrioxamine effectively block cell death in cutaneous T-cell lymphoma cell lines or primary T cells from Sézary patients. We show that inhibition of constitutively active NF-kappaB causes down-regulation of ferritin heavy chain (FHC) that leads to an increase of free intracellular iron, which, in turn, induces massive generation of ROS. Furthermore, direct down-regulation of FHC by siRNA caused a ROS-dependent cell death. Finally, high concentrations of ROS induce cell death of malignant T cells. In contrast, T cells isolated from healthy donors do not display down-regulation of FHC and, therefore, do not show an increase in iron and cell death upon NF-kappaB inhibition. In addition, in a murine T-cell lymphoma model, we show that inhibition of NF-kappaB and subsequent down-regulation of FHC significantly delays tumor growth in vivo. Thus, our results promote FHC as a potential target for effective therapy in lymphomas with aberrant NF-kappaB signaling.
核因子(NF-κB)信号通路的异常激活已被确定为白血病和淋巴瘤中细胞存活及抗凋亡的介质。在此,我们报告,通过抑制NF-κB信号通路诱导的皮肤T细胞淋巴瘤细胞系的细胞死亡不依赖于半胱天冬酶或经典死亡受体。我们发现,细胞内游离铁和活性氧(ROS)是这种细胞死亡的主要介质。抗氧化剂如N-乙酰-L-半胱氨酸和谷胱甘肽或铁螯合剂去铁胺能有效阻断皮肤T细胞淋巴瘤细胞系或 Sézary 患者原代T细胞的细胞死亡。我们表明,抑制组成型激活的NF-κB会导致铁蛋白重链(FHC)下调,进而导致细胞内游离铁增加,这反过来又诱导大量ROS生成。此外,通过小干扰RNA直接下调FHC会导致依赖ROS的细胞死亡。最后,高浓度的ROS诱导恶性T细胞死亡。相比之下,从健康供体分离的T细胞在抑制NF-κB时不会出现FHC下调,因此也不会出现铁含量增加和细胞死亡。此外,在小鼠T细胞淋巴瘤模型中,我们表明抑制NF-κB以及随后FHC的下调会显著延迟体内肿瘤生长。因此,我们的结果表明FHC是具有异常NF-κB信号的淋巴瘤有效治疗的潜在靶点。